Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.65 |
| ▸ | EED | O75530 | 19/20 | 0.65 |
| ▸ | RBBP4 | Q09028 | 19/20 | 0.65 |
| ▸ | SUZ12 | Q15022 | 19/20 | 0.65 |
| ▸ | AEBP2 | Q6ZN18 | 19/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213220 | 0.91 | EED (0.64) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL16212464 | 0.90 | EZH2 (0.68) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL16212636 | 0.90 | EZH2 (0.68) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17713628 | 0.90 | EZH2 (0.68) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL16212562 | 0.89 | EED (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL16212764 | 0.88 | EED (0.60) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17713684 | 0.86 | EZH2 (0.55) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17713650 | 0.85 | EED (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17713670 | 0.85 | EED (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17713687 | 0.85 | EED (0.56) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991980-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-03-09 | — | — | EP | claimed |
| WO-2014177982-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-11-06 | — | — | WO | claimed |
| EP-3119390-A2 | METHODS OF TREATING CANCER | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-01-25 | — | — | EP | disclosed |
| EP-2991980-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015143424-A2 | METHODS OF TREATING CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
| WO-2014177982-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-11-06 | — | — | WO | disclosed |